These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 30319622)

  • 1. The Role of CXC Chemokine Receptors 1-4 on Immune Cells in the Tumor Microenvironment.
    Susek KH; Karvouni M; Alici E; Lundqvist A
    Front Immunol; 2018; 9():2159. PubMed ID: 30319622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Hypoxia on the Expression of CXC Chemokines and CXC Chemokine Receptors-A Review of Literature.
    Korbecki J; Kojder K; Kapczuk P; Kupnicka P; Gawrońska-Szklarz B; Gutowska I; Chlubek D; Baranowska-Bosiacka I
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy.
    Mollica Poeta V; Massara M; Capucetti A; Bonecchi R
    Front Immunol; 2019; 10():379. PubMed ID: 30894861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer.
    Cabrero-de Las Heras S; Martínez-Balibrea E
    World J Gastroenterol; 2018 Nov; 24(42):4738-4749. PubMed ID: 30479461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of CXC chemokines and their receptors in cancer.
    Vandercappellen J; Van Damme J; Struyf S
    Cancer Lett; 2008 Aug; 267(2):226-44. PubMed ID: 18579287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor.
    Li BH; Garstka MA; Li ZF
    Mol Immunol; 2020 Jan; 117():201-215. PubMed ID: 31835202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression and role of CXC chemokines in colorectal cancer.
    Verbeke H; Struyf S; Laureys G; Van Damme J
    Cytokine Growth Factor Rev; 2011; 22(5-6):345-58. PubMed ID: 22000992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.
    Nazari A; Khorramdelazad H; Hassanshahi G
    Int J Clin Oncol; 2017 Dec; 22(6):991-1000. PubMed ID: 29022185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
    Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
    Front Immunol; 2020; 11():585214. PubMed ID: 33613512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy.
    Bule P; Aguiar SI; Aires-Da-Silva F; Dias JNR
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Multifaceted Roles of CXCL9 Within the Tumor Microenvironment.
    Neo SY; Lundqvist A
    Adv Exp Med Biol; 2020; 1231():45-51. PubMed ID: 32060845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor promoting capacity of polymorphonuclear myeloid-derived suppressor cells and their neutralization.
    Groth C; Weber R; Lasser S; Özbay FG; Kurzay A; Petrova V; Altevogt P; Utikal J; Umansky V
    Int J Cancer; 2021 Nov; 149(9):1628-1638. PubMed ID: 34224592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses.
    Hossain F; Majumder S; Ucar DA; Rodriguez PC; Golde TE; Minter LM; Osborne BA; Miele L
    Front Immunol; 2018; 9():1288. PubMed ID: 29915603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor cells educate mesenchymal stromal cells to release chemoprotective and immunomodulatory factors.
    Le Naour A; Prat M; Thibault B; Mével R; Lemaitre L; Leray H; Joubert MV; Coulson K; Golzio M; Lefevre L; Mery E; Martinez A; Ferron G; Delord JP; Coste A; Couderc B
    J Mol Cell Biol; 2020 Apr; 12(3):202-215. PubMed ID: 31504643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multifaceted role of chemokines in solid tumors: From biology to therapy.
    Raza S; Rajak S; Tewari A; Gupta P; Chattopadhyay N; Sinha RA; Chakravarti B
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):1105-1121. PubMed ID: 34979274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential.
    Pi YN; Qi WC; Xia BR; Lou G; Jin WL
    Front Immunol; 2021; 12():697083. PubMed ID: 34295338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
    Kamran N; Chandran M; Lowenstein PR; Castro MG
    Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer.
    Toor SM; Elkord E
    Immunol Cell Biol; 2018 Oct; 96(9):888-897. PubMed ID: 29635843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining epigenetic and immune therapy to overcome cancer resistance.
    Gomez S; Tabernacki T; Kobyra J; Roberts P; Chiappinelli KB
    Semin Cancer Biol; 2020 Oct; 65():99-113. PubMed ID: 31877341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of CXC group chemokines in lung cancer development and progression.
    Spaks A
    J Thorac Dis; 2017 Apr; 9(Suppl 3):S164-S171. PubMed ID: 28446981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.